Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma

Journal of Internal Medicine

Volumn 249, Issue 1, 2001, Pages 69-75

  Bergquist, Annika ^a   Glaumann, H ^a   Stal P ^b   Wang, G S ^a   Broome U ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

Author keywords

Apoptosis; Biliary dysplasia; Cholangiocarcinoma; Sclerosing cholangitits

Indexed keywords

CELL NUCLEUS DNA; DNA FRAGMENT; MONOCLONAL ANTIBODY KI 67; PROTEIN BCL 2; PROTEIN P53;

ADULT; APOPTOSIS; ARTICLE; BILE DUCT; BILE DUCT CARCINOMA; CELL PROLIFERATION; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DYSPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; MALE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCLEROSING CHOLANGITIS;

ADULT; APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS; BILE DUCTS, INTRAHEPATIC; CELL DIVISION; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; DNA FRAGMENTATION; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035136475     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2001.00775.x     Document Type: Article

References (31)

1. Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis
2. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis
3. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case control study
4. Cholangiocarcinoma complicating primary sclerosing cholangitis
5. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis
6. A 3-year prospective study on serum tumour markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis
7. Superficial thrombophlebitis, dysplasia, and cholangiocarcinoma in primary sclerosing cholangitis
8. Biliary dysplasia in primary sclerosing cholangitis as a marker of increased risk of cholangiocarcinoma
9. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
10. Apoptosis in the pathogenesis and treatment of disease
11. Cell death by apoptosis: Basic concepts and disease relevance for the gastroenterologist
12. Apoptosis and hepatobiliary disease
13. p53-dependent apoptosis supresses tumor growth and progression in vivo
14. The p53 tumour suppressor gene
15. Activating mutations in p53 produce a conformational effect. A monoclonal antibody specific for the mutant form
16. Bcl-2 initiates a new category of oncogenes: Regulators of cell death
17. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma
18. Clinicopathologic features of the syndrome of primary sclerosing cholangitis
19. Primary sclerosing cholangitis: A review of its clinical features, cholangiography and hepatic histology
20. An epidemiological study of ulcerative colitis and regional enteritis in the Oxford area
21. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis
22. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease
23. Mechanisms of biliary carcinogenesis: A pathogenetic multi-stage cascade towards cholangiocarcinoma
24. Adenomatous residues in cancerous papilla of Vater
25. Papillary bile duct dysplasia in primary sclerosing cholangitis
26. Mutations in the p53 tumour suppressor gene: Clues to cancer etiology and molecular pathogenesis
27. p53 protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis
28. p53 mutations in dysplastic and neoplastic bile duct epithelium in primary sclerosing cholangitis
29. Apoptosis in human hepatocellular carcinoma and in liver cell dysplasia is correlated with p53 protein immunoreactivity
30. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: A cautionary note
31. Inherent increase of apoptosis in liver tumors: Implications for carcinogenesis and tumor regression